New CAR-T therapy targets Hard-to-Treat lymphoma
NCT ID NCT05741359
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called BRL-201 for people with relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy uses a patient's own immune cells, modified to target cancer cells, and aims to control the disease. About 12-18 adults will participate to check safety and find the best dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhejiang University
RECRUITINGHangzhou, Zhejiang, China
-
Tianjin Institute of Hematology
RECRUITINGTianjin, Tianjin Municipality, China
-
Wuhan Union Hospital
RECRUITINGWuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take on tough blood cancers
- Lymphoma Patients' vaccine response under scrutiny
- Muscle loss may predict CAR-T outcomes in lymphoma
- Off-the-Shelf cell therapy takes on tough lymphoma
- New liquid biopsy could spot hidden brain lymphoma
- New hope for Tough-to-Treat lymphoma: Two-Drug combo enters Mid-Stage trial